Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
Chen
Helen X
HX
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000096:biosynthesis* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense